REGISTERED NUMBER: 03941645 (England and Wales)

Unaudited Financial Statements for the Year Ended 31 December 2024

for

International Bioscience Managers

Limited

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTORS:

Jeremy Curnock Cook

Robert Iggulden

Donald Macpherson

SECRETARY:

Robert Iggulden

REGISTERED OFFICE:

93 Beaumont Road

London

W4 5AJ

REGISTERED NUMBER:

03941645 (England and Wales)

ACCOUNTANTS:

Oculus Accountancy Limited

Chartered Accountants

83 Victoria Street

London

SW1H 0HW

FIXED ASSETS

Investments

4

161,989

161,989

CURRENT ASSETS

Cash at bank

160,469

248,006

CREDITORS

Amounts falling due within one year

5

(32,000

)

(108,870

)

NET CURRENT ASSETS

128,469

139,136

TOTAL ASSETS LESS CURRENT LIABILITIES

290,458

301,125

CAPITAL AND RESERVES

Called up share capital

6

5,721

5,721

Share premium

7

1,788,695

1,788,695

Retained earnings

7

(1,503,958

)

(1,493,291

)

SHAREHOLDERS' FUNDS

290,458

301,125

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 12 November 2025 and were signed on its behalf by:

Robert Iggulden - Director

1.	STATUTORY INFORMATION

International Bioscience Managers Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Consolidation

The company is a parent company subject to the small companies regime. The company and its subsidiary comprise a small group.The company has therefore taken advantage of the option provided by sec 398 of the Companies act 2006 not to prepare group accounts.

Investments in subsidiaries

Investment in Subsidiaries are accounted for at cost less any impairment.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Turnover

Turnover comprises revenue recognised by the company in respect of services provided, and received either in cash or equity or debt instruments in other companies, exclusive of Value Added tax.

Corporate advisory retainers and fund management fees are recognised as services are provided. Success fees are recognised on completion of the event to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

4.	FIXED ASSET INVESTMENTS

Shares in

group

undertakings

£

COST

At 1 January 2024

and 31 December 2024

161,989

NET BOOK VALUE

At 31 December 2024

161,989

At 31 December 2023

161,989

Subsidiary undertakings

The following were subsidiary undertakings of the company:

Bioscience Managers Ltd (incorporated in Australia)

50% of ordinary share capital

The nature of subsidiary undertakings' business was that of fund management.

5.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.12.24

31.12.23

£

£

Other creditors

32,000

108,870

6.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31.12.24

31.12.23

value:

£

£

572,069

Ordinary Share

.01

5,721

5,721

7.

RESERVES

Retained

Share

earnings

premium

Totals

£

£

£

At 1 January 2024

(1,493,291

)

1,788,695

295,404

Deficit for the year

(10,667

)

(10,667

)

At 31 December 2024

(1,503,958

)

1,788,695

284,737

8.	RELATED PARTY DISCLOSURES

International Bioscience Managers Limited director Mr Jeremy Curnock Cook is an executive director of Bioscience Managers Ltd. IBML owns more than 50% of ordinary share capital of the company.